Erythropoietin in the Treatment of Anemia After Autologous Hematopoietic Stem Cell Transplantation

• Status: Unknown status
• Trial end date: 2018-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This is an randomized trial to evaluate the potential benefit of erythropoietin in the treatment of anemia in patients with lymphoma after autologous hematopoietic stem cell transplantation.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking University
• Treatments: Epoetin Alfa; Ferrous succinate; Folic Acid; Hematinics; Hydroxocobalamin; Vitamin B 12; Vitamin B Complex; Vitamins

Criteria

Inclusion Criteria:

• confirmed lymphoma

• first autologous hematopoietic stem cell transplantation

• hemoglobin level less than 100 g/L on day +15 post-transplant

• written informed consent given by patient or his/her guardian if of minor age.

Exclusion Criteria:

• HIV positive

• Known allergy to recombinant human erythropoietin

• Uncontrolled infection